Segall Bryant & Hamill LLC Has $6.99 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Segall Bryant & Hamill LLC lifted its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 43.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,459 shares of the company’s stock after acquiring an additional 58,522 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.26% of SpringWorks Therapeutics worth $6,990,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AlphaQuest LLC lifted its stake in SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after buying an additional 414 shares during the period. KBC Group NV increased its stake in shares of SpringWorks Therapeutics by 59.1% in the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after acquiring an additional 978 shares in the last quarter. Quarry LP lifted its position in shares of SpringWorks Therapeutics by 20.0% during the 3rd quarter. Quarry LP now owns 6,000 shares of the company’s stock valued at $192,000 after acquiring an additional 1,000 shares during the period. Arizona State Retirement System boosted its stake in SpringWorks Therapeutics by 7.5% during the fourth quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock worth $622,000 after acquiring an additional 1,206 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in SpringWorks Therapeutics in the fourth quarter worth $45,000.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ SWTX opened at $46.48 on Thursday. The stock has a market cap of $3.48 billion, a price-to-earnings ratio of -13.36 and a beta of 0.76. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $62.00. The firm’s 50-day simple moving average is $47.48 and its 200 day simple moving average is $39.63.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The company had revenue of $61.55 million for the quarter, compared to analysts’ expectations of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

Insider Transactions at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, CEO Saqib Islam sold 49,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $54.24, for a total value of $2,657,760.00. Following the completion of the sale, the chief executive officer now directly owns 954,869 shares of the company’s stock, valued at approximately $51,792,094.56. This represents a 4.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Badreddin Edris sold 30,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $53.13, for a total transaction of $1,593,900.00. Following the completion of the sale, the chief operating officer now owns 189,712 shares of the company’s stock, valued at approximately $10,079,398.56. This trade represents a 13.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 440,766 shares of company stock worth $24,402,956 in the last quarter. 7.61% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

SWTX has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a research report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Evercore ISI boosted their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Guggenheim lowered their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, SpringWorks Therapeutics has an average rating of “Buy” and an average price target of $73.20.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.